Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.
about
Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF)The sub-optimal response to controlled ovarian stimulation: manageable or inevitable?Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceAnti-Müllerian hormone: ovarian reserve testing and its potential clinical implicationsAdded value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approachIs there a recommended maximum starting dose of FSH in IVF?Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocolDemographic characteristics and clinical profile of poor responders in IVF / ICSI: A comparative study.The role of anti-Müllerian hormone in female fertility and infertility - an overview.A systematic review of tests predicting ovarian reserve and IVF outcome.Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve.The value of human chorionic gonadotropin stimulation test in predicting ovarian response during in-vitro fertilization.Diminished ovarian reserve in the United States assisted reproductive technology population: diagnostic trends among 181,536 cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System.Effect of cancer and cancer treatment on human reproduction.What should be the maximum FSH dose in IVF/ICSI in poor responders?Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cyclesIncreased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve.Approaches to improve the diagnosis and management of infertilityBiological versus chronological ovarian age: implications for assisted reproductive technology.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).Poor responders to controlled ovarian hyperstimulation for in vitro fertilisation (IVF).Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?Trends in 'poor responder' research: lessons learned from RCTs in assisted conception.Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review.A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.An upper limit of gonadotropin dose in patients undergoing ART should be advocated.Association of rs6166 polymorphism with FSH receptor transcript variants and steroid production in human granulosa cell cultures.Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.The carriers of the A/G-G/G allelic combination of the c.2039 A>G and c.-29 G>A FSH receptor polymorphisms retrieve the highest number of oocytes in IVF/ICSI cycles.Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.Follicular and endocrine dose responses according to anti-Müllerian hormone levels in IVF patients treated with a novel human recombinant FSH (FE 999049).Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles.Increasing the Stimulation Dose of rFSH in Unexpected Poor Responders Is Not Associated with Better IVF Outcome
P2860
Q24240361-168674B6-B575-4E96-9276-AD392375C30BQ26800627-AFC81F26-10A4-44AF-AEED-65CF8CC4B364Q26829747-174BDE93-C5F5-4CEE-BA82-27186C493EBBQ28239980-0D4FC545-90CE-4449-A138-C19DEF60D212Q28280088-6AF9A16F-8ED8-444D-8D4E-E11E3AC09C9BQ33287991-9738C390-6A38-4737-B39E-00EED57D4898Q33888265-844B6910-6F45-4962-A990-ACE425AE49EBQ34268692-7A4C15F1-CDE9-404C-9961-EFCC085FBFF7Q34278051-DC51C81A-8FD1-4452-91C6-115FF0B64E3DQ34554644-A7BDD9F9-6C8A-4E45-A12E-84A9ECAD062BQ35100061-7D90A992-0878-4452-B75C-ACEE5D08A95EQ35562391-7840085F-DDFF-4FFD-823A-C7ECEA378DF7Q36030666-5C8719D6-F4D1-4AB1-B0FF-953816080737Q36842760-9BC87C48-5B20-41CE-9605-71175200F2F4Q36892424-3339B28C-5E27-4E2E-9C2F-AD511317DFD5Q36978308-042CBA39-9741-4AB0-847F-F0CEDB073450Q36995774-5299DE29-AEF4-4192-82B4-790F17BED2B5Q37214916-3F22F377-C04C-4290-9CB8-39B627A81149Q37393945-7B799E4F-37FE-465D-827F-F78732D6F293Q37606149-E1E0D0C3-E217-4F77-A806-8CA92F48A58FQ37942272-1409B717-C0F6-4CC5-91C7-395FDDC39548Q38635556-73B84816-BD14-4898-BBBD-DF9E76C3CEB1Q38722378-7EE2E4DA-F982-45FD-B3F3-B470F8D62EBBQ38968422-A58F147E-986C-4873-807B-E17808DD7B24Q39193902-4CAE419C-0989-4A6D-AB51-CF5558207EEFQ39654118-C96E44E0-92E7-4638-B3FE-C1EAF5F88ECAQ43857450-8AA347B8-6AF3-4D6E-9CAA-5B464B8006DAQ47221797-0E048F01-58F9-490A-ABD4-C3C55ECB3305Q48536525-32AC3BF2-5A80-439C-B20E-E7829C2A84A3Q48594365-7EEAA23E-EDFA-4BDA-A622-A69767FC7589Q48605923-5242F613-74F7-4467-B57D-8654A421FEA4Q49171172-0A2E5FCE-FAF6-42B5-AA0D-7DC7D1E96C7EQ50927458-C3CF9EED-A7BE-4D82-94EA-04F8C330BE24Q58914664-34A3589B-369B-4BAD-B6FA-B17BBB306B2B
P2860
Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Expected poor responders on th ...... a randomized controlled trial.
@en
Expected poor responders on th ...... a randomized controlled trial.
@nl
type
label
Expected poor responders on th ...... a randomized controlled trial.
@en
Expected poor responders on th ...... a randomized controlled trial.
@nl
prefLabel
Expected poor responders on th ...... a randomized controlled trial.
@en
Expected poor responders on th ...... a randomized controlled trial.
@nl
P2093
P2860
P356
P1433
P1476
Expected poor responders on th ...... a randomized controlled trial.
@en
P2093
Broekmans FJ
Habbema JD
Klinkert ER
te Velde ER
P2860
P304
P356
10.1093/HUMREP/DEH663
P407
P577
2004-12-09T00:00:00Z